Lisata’s Marea Therapeutics Announces First Patient Dosed In Its Phase 2 Clinical Trial Of MAR002 For Treatment Of Acromegaly

Marea Therapeutics, a subsidiary of Lisata Therapeutics, has announced the dosing of the first patient in its Phase 2 clinical trial for MAR002, aimed at treating acromegaly. This investigational therapy, a first-in-class allosteric monoclonal antibody, has shown promising results in a Phase 1 trial, demonstrating deep and durable IGF-1 suppression with potential for biweekly dosing, unlike the current daily injections. Acromegaly is a chronic disorder caused by excess growth hormone, leading to serious health complications if untreated.